Strepsils Original Lozenges Blister No. 24

Instructions Strepsils Original Lozenges Blister No. 24

Composition

active ingredients: 2,4-dichlorobenzyl alcohol, amylmetacresol;

1 lollipop contains: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg;

excipients: star anise oil, peppermint oil, levomenthol, tartaric acid, Ponceau 4R (E 124), carmoisine (E 122), sucrose solution, glucose solution.

Dosage form

Lollipops.

Main physicochemical properties: round red lollipops with an "S" embossed on both sides.

Pharmacotherapeutic group

Drugs used in throat diseases. Antiseptics. Dichlorobenzyl alcohol. ATX code R02A A03.

Pharmacological properties

Pharmacodynamics

The drug has antiseptic properties. Active against a wide range of gram-positive and gram-negative microorganisms; has an antifungal effect. The effectiveness of the drug is due to the presence of two broad-spectrum antibacterial components that relieve sore throat and reduce inflammation. Amylmetacresol destroys the structure of bacterial proteins, which provides a bactericidal effect. 2,4-dichlorobenzyl alcohol has a bacteriostatic effect due to dehydration of the bacterial cell.

Strepsils® Original contains star anise oil and peppermint oil, which relieve sore throats.

Pharmacokinetics

Due to the low absorption, the drug is a topical agent. Given this, pharmacokinetic parameters have not been determined.

Indication

Symptomatic treatment of infectious and inflammatory diseases of the oral cavity and pharynx.

Contraindication

Hypersensitivity to any component of the drug.

Interaction with other medicinal products and other types of interactions

Interaction studies have not been conducted.

Application features

The indicated maximum dose should not be exceeded.

If symptoms persist for 3 days, you should consult a doctor for additional adjustment of the treatment regimen.

Patients with rare hereditary diseases accompanied by fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency should not use this drug. Patients with diabetes should take into account that 1 lollipop contains approximately 2.6 g of sugar.

Use during pregnancy or breastfeeding

Pregnancy: The safety of this medicine during pregnancy or breast-feeding has not been fully established, but no risk is expected during these periods. However, as with all medicines, caution should be exercised during pregnancy or breast-feeding.

Breast-feeding: It is not known whether 2,4-dichlorobenzyl alcohol, amylmetacresol or metabolites are excreted in human milk. A risk to the newborn/infants cannot be excluded.

There are no data on the effect on fertility.

Ability to influence reaction speed when driving vehicles or other mechanisms

The effect on the ability to drive or operate other mechanisms is absent or insignificant.

Method of administration and doses

For oromucosal use.

Use the lowest effective dose necessary to relieve symptoms for the shortest period of time.

It is recommended for adults and children over 6 years of age to take 1 lollipop every 2-3 hours. The lollipop should be slowly sucked until completely dissolved. Do not use more than 12 lollipops in 24 hours. If symptoms do not improve or worsen within 3 days, consult a doctor.

No dose adjustment is necessary for elderly patients.

Children. Given the dosage form, the drug is contraindicated in children under 6 years of age.

Overdose

In the unlikely event of overdose, serious side effects are not expected. Some gastrointestinal discomfort may occur. Treatment is symptomatic.

Side effects

The following adverse reactions have been observed with short-term use:

2,4-dichlorobenzyl alcohol and amylmetacresol in non-prescription doses. Other adverse reactions may occur in the treatment of chronic diseases and with prolonged use.

Adverse reactions are classified by system organ class and frequency. The frequency is defined as follows: very common: ≥1/10; common: ≥1/100 and <1/10; uncommon: ≥1/1,000 and <1/100; rare: ≥1/10,000 and <1/1,000; very rare: <1/10,000; not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

From the immune system.

Uncommon: hypersensitivity reactions, including rash, urticaria and angioedema, which may include swelling of the face, neck, throat or tongue, which may affect breathing.

From the respiratory tract and mediastinal organs.

Uncommon: pharyngeal oedema (swelling of the throat).

Uncommon: oral discomfort (burning sensation in the mouth), throat irritation (burning sensation in the throat), oral paraesthesia (tingling sensation in the mouth), oral oedema. Rare: glossodynia (tongue pain). Very rare: dyspepsia, nausea, stomatitis. Not known: abdominal pain.

On the skin and subcutaneous tissue.

Not known: skin rash, itching, erythema.

Expiration date

3 years.

Storage conditions

Store at a temperature not exceeding 25 ° C. Keep out of the reach of children.

Packaging

12 lozenges in a blister; 2 blisters in a cardboard box.

Vacation category

Without a prescription.

Producer

Reckitt Benckiser Healthcare International Limited/

Reckitt Benckiser Healthcare International Limited

Address

Nottingham site, Thane Road, Nottingham, NG90 2DB, United Kingdom/

Nottingham Site, Thane Road, Nottingham, NG90 2DB, United Kingdom.